Abstract：
Omalizumab (OMA) dramatically improves disease control and quality of life in patients with chronic urticaria (CU).
We aimed to evaluate the discontinuation patterns of OMA and their determinants in a cohort of French patients with CU.
We conducted a retrospective multicenter study in 9 French tertiary referral hospitals. All patients diagnosed with either spontaneous (CSU) and/or inducible (CIndU) CU who received at least 1 injection of OMA between 2009 and 2021 were included. We analyzed OMA drug survival and investigated possible determinants using Kaplan-Meier curves and log-rank tests.
A total of 878 patients were included in this study; 48.8% had CSU, 10.1% CIndU, and 41.1% a combination of both. OMA was discontinued in 408 patients, but the drug was later reintroduced in 50% of them. The main reason for discontinuing treatment was the achievement of a well-controlled disease in 50% of patients. Half of the patients were still being treated with OMA 2.4 years after the initiation of treatment. Drug survival was shorter in patients with CIndU and in those with an autoimmune background. In atopic patients, OMA was discontinued earlier in patients achieving a well-controlled disease. A longer OMA drug survival was observed in patients with a longer disease duration at initiation.
In French patients with CU, the drug survival of OMA appears to be longer than that observed in previous studies conducted elsewhere, highlighting discrepancies in prescription and reimbursement possibilities. Further studies are warranted to develop customized OMA treatment schemes based on individual patterns.
We aimed to evaluate the discontinuation patterns of OMA and their determinants in a cohort of French patients with CU.
We conducted a retrospective multicenter study in 9 French tertiary referral hospitals. All patients diagnosed with either spontaneous (CSU) and/or inducible (CIndU) CU who received at least 1 injection of OMA between 2009 and 2021 were included. We analyzed OMA drug survival and investigated possible determinants using Kaplan-Meier curves and log-rank tests.
A total of 878 patients were included in this study; 48.8% had CSU, 10.1% CIndU, and 41.1% a combination of both. OMA was discontinued in 408 patients, but the drug was later reintroduced in 50% of them. The main reason for discontinuing treatment was the achievement of a well-controlled disease in 50% of patients. Half of the patients were still being treated with OMA 2.4 years after the initiation of treatment. Drug survival was shorter in patients with CIndU and in those with an autoimmune background. In atopic patients, OMA was discontinued earlier in patients achieving a well-controlled disease. A longer OMA drug survival was observed in patients with a longer disease duration at initiation.
In French patients with CU, the drug survival of OMA appears to be longer than that observed in previous studies conducted elsewhere, highlighting discrepancies in prescription and reimbursement possibilities. Further studies are warranted to develop customized OMA treatment schemes based on individual patterns.
摘要：
背景：奥马珠单抗（OMA）可显著改善慢性荨麻疹（CU）患者的疾病控制和生活质量。
目的：我们旨在评估法国CU患者队列中OMA的停药模式及其决定因素。
方法：我们在9家法国三级转诊医院进行了一项多中心回顾性研究。包括所有诊断为自发性（CSU）和/或诱导型（CIndU）CU的患者，这些患者在2009年至2021年之间接受了至少一次OMA注射。我们分析了OMA药物的存活率，并使用Kaplan-Meier曲线和对数秩检验研究了可能的决定因素。
结果：本研究共纳入878例患者；48.8%患有CSU，10.1%CIndU，和41.1%两者的组合。408名患者停用了OMA，但后来在其中50％的患者中重新引入了该药物。停止治疗的主要原因是50％的患者获得了良好的疾病控制。一半的患者在开始治疗2.4年后仍在接受OMA治疗。具有CIndU和具有自身免疫背景的患者的药物生存期较短。在特应性患者中，在疾病控制良好的患者中，OMA较早停止。在开始时具有较长疾病持续时间的患者中观察到较长的OMA药物生存期。
结论：在法国CU患者中，OMA的药物生存期似乎比以前在其他地方进行的研究中观察到的更长，突出处方和报销可能性的差异。需要进一步的研究来开发基于个体模式的定制OMA治疗方案。
目的：我们旨在评估法国CU患者队列中OMA的停药模式及其决定因素。
方法：我们在9家法国三级转诊医院进行了一项多中心回顾性研究。包括所有诊断为自发性（CSU）和/或诱导型（CIndU）CU的患者，这些患者在2009年至2021年之间接受了至少一次OMA注射。我们分析了OMA药物的存活率，并使用Kaplan-Meier曲线和对数秩检验研究了可能的决定因素。
结果：本研究共纳入878例患者；48.8%患有CSU，10.1%CIndU，和41.1%两者的组合。408名患者停用了OMA，但后来在其中50％的患者中重新引入了该药物。停止治疗的主要原因是50％的患者获得了良好的疾病控制。一半的患者在开始治疗2.4年后仍在接受OMA治疗。具有CIndU和具有自身免疫背景的患者的药物生存期较短。在特应性患者中，在疾病控制良好的患者中，OMA较早停止。在开始时具有较长疾病持续时间的患者中观察到较长的OMA药物生存期。
结论：在法国CU患者中，OMA的药物生存期似乎比以前在其他地方进行的研究中观察到的更长，突出处方和报销可能性的差异。需要进一步的研究来开发基于个体模式的定制OMA治疗方案。
